IceCure Reports Financial & Operational Results for the Nine Months Ended September 30, 2026: 83% Year-Over-Year Growth in U.S. Sales and Major Growth in U.S. Commercial Reach to 21 States
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
IceCure Medical (ICCM) reported 83% year-over-year U.S. sales growth for ProSense and its cryoprobes in the nine months ended September 30, 2026. Total revenue rose approximately 26% to $2.642 million, and gross profit rose to $762,000 from $626,000. Net loss widened to $12.995 million from $10.811 million, and operating cash use rose to $12.575 million from $9.555 million. Cash and equivalents stood at $8.220 million at September 30.
U.S. commercial reach expanded to 21 states in Q3 2026 from 11 in Q3 2025. IceCure received Chinese marketing approval for ProSense and signed an exclusive distribution agreement in the Netherlands. The ChoICE study of tumor freezing for low-risk breast cancer opened its first sites in Q3. After quarter-end, three more sites joined, the first two patients enrolled, and the first treatment was completed.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Major pointNet proceeds from shares, warrants and pre-funded warrants totaled $12.020 million through September 2026 4.2× market cap
- Major pointChina marketing approval permits IceCure to market ProSense as a Class III medical device
- Moderate pointU.S. ProSense and cryoprobe sales rose 83% year over year in the first nine months of 2026
- Moderate pointTotal revenue rose approximately 26% to $2.642 million from $2.100 million year over year through September
- Moderate pointU.S. commercial reach expanded to 21 states in Q3 2026 from 11 in Q3 2025
- Moderate pointExclusive Netherlands distribution agreement signed for ProSense systems
7 minor points
- Minor pointGross profit rose approximately 22% to $762,000 from $626,000 year over year through September
- Minor pointBasic and diluted net loss per share narrowed to $3.57 from $5.40 year over year through September
- Minor pointFirst ChoICE treatment was completed after quarter-end at West Cancer Center in Germantown, Tennessee
- Minor pointFirst two ChoICE patients enrolled after quarter-end at two U.S. clinical sites
- Minor pointChoICE site expansion began with the first sites opening in Q3; three more joined after quarter-end
- Minor pointU.S. commercial team added sales, marketing and clinical support staff in Q3 2026
- Minor pointWarrant and pre-funded warrant exercises provided $10,000 through September 2026
Negative
- Major pointNet loss widened to $12.995 million from $10.811 million year over year through September
- Major pointOperating cash use rose to $12.575 million from $9.555 million year over year through September
- Major pointOrdinary shares outstanding rose to 5,563,265 at September 30, 2026, from 2,437,410 at December 31, 2025
- Minor pointOperating loss widened to $12.991 million from $10.878 million year over year through September
- Minor point. Forward-looking: it has not happened yet and may not happen.Warrants and pre-funded warrants issued can dilute existing holders when exercised
9 minor points
- Minor pointResearch and development expenses rose to $6.557 million from $5.137 million year over year through September
- Minor pointCash and cash equivalents fell to $8.220 million at September 30, 2026, from $8.897 million at December 31, 2025
- Minor pointSales and marketing expenses rose to $3.669 million from $3.061 million year over year through September
- Minor pointCost of revenue rose to $1.880 million from $1.474 million year over year through September
- Minor pointLong-term lease liabilities rose to $452,000 at September 30, 2026, from $13,000 at December 31, 2025
- Minor pointShareholders’ equity fell to $8.774 million at September 30, 2026, from $9.051 million at December 31, 2025
- Minor pointGeneral and administrative expenses rose to $3.527 million from $3.306 million year over year through September
- Minor pointProperty and equipment purchases rose to $154,000 from $31,000 year over year through September
- Minor pointNet finance expense was $4,000, compared with $67,000 in net finance income a year earlier through September
News Explained
Net issuance proceeds were 12,020 thousand dollars, against operating cash use of 12,575 thousand dollars for the nine months.
In reporting results for the nine months ended
For the same nine-month period, the company reported net proceeds of
Key Figures
- Revenue
- Approximately $2.6 million; up approximately 26%
- Nine months ended September 30, 2026; $2.1 million in the corresponding 2025 period
- U.S. sales growth
- 83% year over year
- First nine months of 2026
- U.S. commercial reach
- 21 states
- Third quarter of 2026; 11 states in the third quarter of 2025
- Gross profit
- $762,000; increased approximately 22%
- Nine months ended September 30, 2026; $626,000 in the corresponding 2025 period
- Research and development expenses
- $6.5 million
- Nine months ended September 30, 2026; $5.1 million in the corresponding 2025 period
- Net loss
- $12.9 million
- Nine months ended September 30, 2026; $10.8 million in the corresponding 2025 period
- Cash and cash equivalents
- Approximately $8.2 million
- As of September 30, 2026
Previous Earnings Reports
-
First-half revenue rose 45% as net loss widened amid increased commercial and study spending.
-
Comparable nine-month results established $2.1 million revenue and $10.8 million net loss.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
cryoablation medical
institutional review board medical
class iii medical device regulatory
adjuvant endocrine therapy medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Third Quarter 2026 Operational and Clinical Highlights
83% Growth inU.S . Sales:U.S . sales of ProSense® and its cryoprobes doubled year over year during the first nine months of 2026 compared to the same period in 2025.26% Year-Over-Year Revenue Growth: Total revenues for the first nine months of 2026 increased to approximately , compared to$2.6 million in the corresponding period of 2025.$2.1 million - Expanded
U.S . Commercial Reach: The Company's commercial presence expanded from 11 states in the third quarter of 2025 to 21 states in the third quarter of 2026. - Continued Progress in the ChoICE Study: The Company's post-marketing study (the "ChoICE" Study") evaluating ProSense® cryoablation for the local treatment of low-risk breast cancer launched the first clinical sites after Institutional Review Board ("IRB") approval at West Cancer Center & Research Institute (the "West Cancer Center") in
Germantown, TN and Adventist Health Glendale inGlendale, CA. - International Commercial and Regulatory Progress: Received regulatory approval from
China's National Medical Products Administration to market ProSense® as a Class III medical device and signed an exclusive distribution agreement for ProSense® cryoablation systems inthe Netherlands .
"We believe the first nine months of 2026 demonstrate the progress we made in translating our regulatory and clinical achievements into commercial growth, particularly in
ChoICE Study Moving Forward:
Subsequent to the end of the third quarter of 2026, IceCure announced additional progress in its ChoICE Study:
- Three clinical sites joined the Company's study, including Legacy Health in
Portland, Oregon . - The Company announced the enrollment of the first two patients in the ChoICE Study at two
U.S . clinical sites: West Cancer Center inTennessee and Adventist Health Glendale inCalifornia . - The Company announced the successful completion of the first ProSense® cryoablation treatment in the ChoICE Study. The first patient was treated at West Cancer Center in
Germantown, Tennessee , by Dr. Richard E. Fine, MD, FACS.
Additional Third Quarter of 2026 Successes:
- Expanded
U.S . Commercial Team: Strengthened theU.S . sales and marketing organization by adding dedicated professionals in key territories, includingNew York ,Southern California and the Midwest, andFlorida , as well as additional clinical support personnel to support physician training and adoption of ProSense®. - Participation in Leading Medical Events: Participated in key medical and industry events, including Aptitude Health's Targeted Medical Education ("TME") Take the Lead in Breast Cancer Fall Summit 2026 in
New Orleans, LA and the 2026 European Society of Breast Imaging ("EUSOBI") Congress in Maastricht,Netherlands , engaging with leading breast cancer specialists and the broader medical community. - Strengthened Clinical Evidence: Highlighted two new peer-reviewed scientific publications supporting the role of cryoablation in breast cancer treatment de-escalation, including publications addressing early-stage breast cancer and axillary lymph node metastases.
- Professional Recognition of Cryoablation: The Society of Interventional Oncology ("SIO") submitted a formal petition to the National Comprehensive Cancer Network ("NCCN") to include percutaneous cryoablation as a treatment option in its breast cancer guidelines, potentially broadening the range of treatment options available to eligible patients.
Financial Results for the Nine Months Ended September 30, 2026
Total revenues for the nine months ended September 30, 2026 increased approximately
Gross profit for the nine months ended September 30, 2026 increased approximately 22% to
Research and development expenses for the nine months ended September 30, 2026 were
Sales and marketing expenses were
General and administrative expenses were
Operating loss for the nine months ended September 30, 2026 was
Net loss for the nine months ended September 30, 2026, was
As of September 30, 2026, the Company's cash and cash equivalents totaled approximately
Conference call & webcast info:
Wednesday, November 18, 2026, at 10:00 am EST
US: 1-888-407-2553
A live webcast will be available at: https://www.veidan-conferenceing.com/icecure
A recording of the webcast will be available at: https://ir.icecure-medical.com/
About IceCure Medical
IceCure Medical (NASDAQ: ICCM) develops and markets advanced liquid-nitrogen-based cryoablation therapy systems for the destruction of tumors (benign and cancerous) by freezing, as a safe and effective minimally invasive option to surgical tumor removal, with the primary focus areas being breast, kidney, bone and lung cancer. The Company's flagship ProSense® system is marketed and sold worldwide for the indications cleared and approved to date including in the U.S., Europe, and Asia.
ProSense® cryoablation became the first-and-only medical device cleared by the FDA for the local treatment of breast cancer in patients aged 70 years and older with biologically low-risk tumors ≤1.5 cm in size who are treated with adjuvant endocrine therapy, including patients who are not eligible for surgery.
Forward Looking Statements
This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be covered by the "safe harbor" created by those sections. Forward-looking statements, which are based on certain assumptions and describe our future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as "believe," "expect," "may," "should," "could," "seek," "intend," "plan," "goal," "estimate," "anticipate" or other comparable terms. For example, the Company is using forward-looking statements when it discusses its belief that the first nine months of 2026 demonstrate the progress the Company has made in translating its regulatory and clinical achievements into commercial growth; that the ChoICE Study is building the clinical foundation for broader adoption of ProSense®; that the Company's developments position it to continue driving physician adoption and expanding patient access to ProSense®; the continued expansion of its U.S. commercial footprint, active installed base clinic support personnel and physician adoption; the addition of IRB-approved U.S. clinical sites for the CHoICE Study to support physician adoption; and the belief that professional recognition of cryoablation through the petition submitted by the SIO can potentially broaden the range of treatment options available to eligible patients. Historical results of scientific research and clinical and preclinical trials do not guarantee that the conclusions of future research or trials will suggest identical or even similar conclusions. Important factors that could cause actual results, developments and business decisions to differ materially from those anticipated in these forward-looking statements include, among others: the Company's planned level of revenues and capital expenditures; the Company's available cash and its ability to obtain additional funding; the Company's ability to market and sell its products; legal and regulatory developments in the United States and other countries; the Company's ability to maintain its relationships with suppliers, distributors and other partners; the Company's ability to maintain or protect the validity of its patents and other intellectual property; the Company's ability to expose and educate medical professionals about its products; political, economic and military instability in the Middle East, specifically in Israel; as well as those factors set forth in the Risk Factors section of the Company's Annual Report on Form 20-F for the year ended December 31, 2025 filed with the SEC on March 17, 2026, and other documents filed with or furnished to the SEC which are available on the SEC's website, www.sec.gov. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.
Investor Relations:
Meir Peleg, CFO
+1-888-902-5716
|
ICECURE MEDICAL LTD. |
|
|||||||
|
CONDENSED CONSOLIDATED STATEMENTS OF FINANCIAL POSITION |
|
|||||||
|
|
|
|||||||
|
|
|
As of |
|
|
As of |
|
||
|
|
|
(Unaudited) |
|
|
|
|
||
|
|
|
|
|
|||||
|
|
|
|
|
|
|
|
||
|
ASSETS |
|
|
|
|
|
|
||
|
CURRENT ASSETS |
|
|
|
|
|
|
||
|
Cash and cash equivalents |
|
|
8,220 |
|
|
|
8,897 |
|
|
Trade receivables |
|
|
391 |
|
|
|
331 |
|
|
Inventory |
|
|
2,578 |
|
|
|
2,625 |
|
|
Prepaid expenses and other receivables |
|
|
1,298 |
|
|
|
752 |
|
|
Total current assets |
|
|
12,487 |
|
|
|
12,605 |
|
|
|
|
|
|
|
|
|
|
|
|
NON-CURRENT ASSETS |
|
|
|
|
|
|
|
|
|
Right-of-use assets |
|
|
729 |
|
|
|
239 |
|
|
Property and equipment, net |
|
|
940 |
|
|
|
993 |
|
|
Long-term restricted deposits |
|
|
53 |
|
|
|
51 |
|
|
Total non-current assets |
|
|
1,722 |
|
|
|
1,283 |
|
|
TOTAL ASSETS |
|
|
14,209 |
|
|
|
13,888 |
|
|
|
|
|
|
|
|
|
|
|
|
LIABILITIES AND SHAREHOLDERS' EQUITY |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CURRENT LIABILITIES |
|
|
|
|
|
|
|
|
|
Trade payables |
|
|
1,071 |
|
|
|
863 |
|
|
Lease liabilities |
|
|
255 |
|
|
|
204 |
|
|
Employees and employees related benefits |
|
|
3,024 |
|
|
|
2,659 |
|
|
Other current liabilities |
|
|
633 |
|
|
|
1,098 |
|
|
Total current liabilities |
|
|
4,983 |
|
|
|
4,824 |
|
|
|
|
|
|
|
|
|
|
|
|
NON-CURRENT LIABILITIES |
|
|
|
|
|
|
|
|
|
Long-term lease liabilities |
|
|
452 |
|
|
|
13 |
|
|
Total non-current liabilities |
|
|
452 |
|
|
|
13 |
|
|
|
|
|
|
|
|
|
|
|
|
SHAREHOLDERS' EQUITY |
|
|
|
|
|
|
|
|
|
Ordinary shares, No par value; Authorized 2,500,000,000 shares; Issued and |
|
|
|
|
|
|
|
|
|
Additional paid-in capital |
|
|
142,205 |
|
|
|
129,487 |
|
|
Accumulated deficit |
|
|
(133,431) |
|
|
|
(120,436) |
|
|
Total shareholders' equity |
|
|
8,774 |
|
|
|
9,051 |
|
|
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY |
|
|
14,209 |
|
|
|
13,888 |
|
|
ICECURE MEDICAL LTD. |
|
|||||||
|
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS |
|
|||||||
|
|
|
|||||||
|
|
|
Nine months ended |
|
|||||
|
|
|
2026 |
|
|
2025 |
|
||
|
|
|
|
|
|||||
|
Revenues |
|
|
2,642 |
|
|
|
2,100 |
|
|
Cost of revenues |
|
|
1,880 |
|
|
|
1,474 |
|
|
Gross profit |
|
|
762 |
|
|
|
626 |
|
|
Research and development expenses |
|
|
6,557 |
|
|
|
5,137 |
|
|
Sales and marketing expenses |
|
|
3,669 |
|
|
|
3,061 |
|
|
General and administrative expenses |
|
|
3,527 |
|
|
|
3,306 |
|
|
Operating loss |
|
|
12,991 |
|
|
|
10,878 |
|
|
Finance expenses (income), net |
|
|
4 |
|
|
|
(67) |
|
|
|
|
|
|
|
|
|
|
|
|
Net loss and comprehensive loss |
|
|
12,995 |
|
|
|
10,811 |
|
|
Basic and diluted net loss per share |
|
|
3.57 |
|
|
|
5.4 |
|
|
Weighted average number of shares outstanding used in |
|
|
3,637,322 |
|
|
|
2,018,573 |
|
|
ICECURE MEDICAL LTD. |
||||||||||
|
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS |
||||||||||
|
|
||||||||||
|
|
|
Nine months ended |
|
|||||||
|
|
|
2026 |
|
|
2025 |
|
|
|||
|
|
|
|
|
|||||||
|
Cash flows from operating activities |
|
|
|
|
|
|
|
|||
|
|
|
|
|
|
|
|
|
|||
|
Net loss |
|
(12,995) |
|
|
(10,811) |
|
|
|||
|
Adjustments to reconcile net loss to net cash used in operating activities: |
|
|
|
|
|
|
|
|
|
|
|
Depreciation |
|
|
207 |
|
|
|
224 |
|
|
|
|
Share-based compensation |
|
|
687 |
|
|
|
1,102 |
|
|
|
|
Exchange rate changes in cash and cash equivalents and long-term restricted |
|
|
(24) |
|
|
|
118 |
|
|
|
|
Other finance cost |
|
|
- |
|
|
|
(34) |
|
|
|
|
Changes in assets and liabilities: |
|
|
|
|
|
|
|
|
|
|
|
Decrease (increase) in trade receivables |
|
|
(60) |
|
|
|
117 |
|
|
|
|
Decrease (increase) in prepaid expenses and other receivables |
|
|
(546) |
|
|
|
145 |
|
|
|
|
Decrease (increase) in inventory |
|
|
47 |
|
|
|
(723) |
|
|
|
|
Decrease in right of use assets |
|
|
228 |
|
|
|
251 |
|
|
|
|
Increase (decrease) in trade payables |
|
|
208 |
|
|
|
(81) |
|
|
|
|
Decrease in lease liabilities |
|
|
(227) |
|
|
|
(212) |
|
|
|
|
Increase in employees and employees related liabilities |
|
|
365 |
|
|
|
595 |
|
|
|
|
Decrease in other current liabilities |
|
|
(465) |
|
|
|
(246) |
|
|
|
|
Net cash used in operating activities |
|
|
(12,575) |
|
|
|
(9,555) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash flows from investing activities |
|
|
|
|
|
|
|
|
|
|
|
Investment in short-term deposits |
|
|
- |
|
|
|
(5,000) |
|
|
|
|
Purchase of property and equipment |
|
|
(154) |
|
|
|
(31) |
|
|
|
|
Net cash used in investing activities |
|
|
(154) |
|
|
|
(5,031) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash flows from financing activities: |
|
|
|
|
|
|
|
|
|
|
|
Proceeds from issuance of ordinary shares, warrants and pre-funded warrants, net |
|
|
12,020 |
|
|
|
12,114 |
|
|
|
|
Proceeds from exercise of warrants and pre-funded warrants |
|
|
10 |
|
|
|
- |
|
|
|
|
Net cash provided by financing activities |
|
|
12,030 |
|
|
|
12,114 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Decrease in cash and cash equivalents |
|
|
(699) |
|
|
|
(2,472) |
|
|
|
|
Cash and cash equivalents at beginning of the year |
|
|
8,897 |
|
|
|
7,564 |
|
|
|
|
Effect of exchange rate fluctuations on balances of cash and cash equivalents |
|
|
22 |
|
|
|
(121) |
|
|
|
|
Cash and cash equivalents at end of period |
|
|
8,220 |
|
|
|
4,971 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Non-cash activities |
|
|
|
|
|
|
|
|
|
|
|
Obtaining a right-of-use asset in exchange for a lease liability |
|
|
718 |
|
|
|
41 |
|
|
|
View original content to download multimedia:https://www.prnewswire.com/news-releases/icecure-reports-financial--operational-results-for-the-nine-months-ended-september-30-2026-83-year-over-year-growth-in-us-sales-and-major-growth-in-us-commercial-reach-to-21-states-302943738.html
SOURCE IceCure Medical
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.